The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline
Abstract
Background: Docosahexaenoic acid (DHA) plays an important role in neural function. Decreases in plasma DHA are associated with cognitive decline in healthy elderly adults and in patients with Alzheimer's disease. Higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in age‐related cognitive decline (ARCD) have not been fully examined. Objective: Determine effects of DHA administration on improving cognitive functions in healthy older adults with ARCD. Methods: Randomized, double‐blind, placebo‐controlled, clinical study was conducted at 19 U.S. clinical sites. A total of 485 healthy subjects, aged ≥55 with Mini‐Mental State Examination >26 and a Logical Memory (Wechsler Memory Scale III) baseline score ≥1 standard deviation below younger adults, were randomly assigned to 900 mg/d of DHA orally or matching placebo for 24 weeks. The primary outcome was the CANTAB Paired Associate Learning (PAL), a visuospatial learning and episodic memory test. Results: Intention‐to‐treat analysis demonstrated significantly fewer PAL six pattern errors with DHA versus placebo at 24 weeks (difference score, −1.63 ± 0.76 [−3.1, −0.14, 95% CI], P = .03). DHA supplementation was also associated with improved immediate and delayed Verbal Recognition Memory scores (P < .02), but not working memory or executive function tests. Plasma DHA levels doubled and correlated with improved PAL scores (P < .02) in the DHA group. DHA was well tolerated with no reported treatment‐related serious adverse events. Conclusions: Twenty‐four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. Trial Registration: Clinicaltrials.gov, Identifier: NCT0027813.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191259 · Cited by 3,908
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135
Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., & Rabbitt, P. (1994) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106735 · Cited by 1,078
Lauritzen, L. (2001) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00017-5 · Cited by 1,063
Research works printed but not linked: 1
- 10.1017/S1355617702811067 · DOI
Cited by
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“In other clinical studies, administration of DHA alone also had no affection on the cognitive impairment of AD patients.(551,552) These diverse outcomes may be resulted from the variable quality of ω-3 PUFA supplements on the market(553); larger and more rigorous clinical trials on the effect of ω-3 PUFA in AD treatme…”
BackgroundDyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
Andrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
Nutrition and prevention of cognitive impairment
Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30338-7 · Cited by 612
Bazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441
Metadata
- Authors
- Yurko‐Mauro, K., McCarthy, D., Rom, D., Nelson, E. B., Ryan, A. S., Blackwell, A., Salem, N., Stedman, M., & MIDAS Investigators
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2010-05-03
- Volume
- 6
- Issue
- 6
- Pages
- 456-464
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2053771014
- Cited by
- 579
- References
- 42
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline. https://app.cochat.ai/papers/10.1016/j.jalz.2010.01.013
- The paper
- Yurko‐Mauro, K., McCarthy, D., Rom, D., Nelson, E. B., Ryan, A. S., Blackwell, A., Salem, N., Stedman, M., & MIDAS Investigators. (2010). Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive decline. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2010.01.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
